Atara Biotherapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Atara Biotherapeutics is Pascal Touchon, benoemd in Jun2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.38M, bestaande uit 16.5% salaris en 83.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.58% van de aandelen van het bedrijf, ter waarde € 248.65K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 5.3 jaar.

Belangrijke informatie

Pascal Touchon

Algemeen directeur

US$4.4m

Totale compensatie

Percentage CEO-salaris	16.5%
Dienstverband CEO	5.3yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Pascal Touchon's beloning veranderd ten opzichte van Atara Biotherapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$181m
Mar 31 2024	n/a	n/a	-US$233m
Dec 31 2023	US$4m	US$723k	-US$276m
Sep 30 2023	n/a	n/a	-US$290m
Jun 30 2023	n/a	n/a	-US$305m
Mar 31 2023	n/a	n/a	-US$215m
Dec 31 2022	US$5m	US$718k	-US$228m
Sep 30 2022	n/a	n/a	-US$247m
Jun 30 2022	n/a	n/a	-US$248m
Mar 31 2022	n/a	n/a	-US$350m
Dec 31 2021	US$5m	US$681k	-US$340m
Sep 30 2021	n/a	n/a	-US$328m
Jun 30 2021	n/a	n/a	-US$318m
Mar 31 2021	n/a	n/a	-US$311m
Dec 31 2020	US$5m	US$655k	-US$307m
Sep 30 2020	n/a	n/a	-US$304m
Jun 30 2020	n/a	n/a	-US$301m
Mar 31 2020	n/a	n/a	-US$298m
Dec 31 2019	US$7m	US$319k	-US$291m

Compensatie versus markt: De totale vergoeding ($USD 4.38M ) Pascal } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 483.75K ).

Compensatie versus inkomsten: De vergoeding van Pascal is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Pascal Touchon (61 yo)

5.3yrs

Tenure

US$4,375,125

Compensatie

Dr. Pascal Touchon, D.V.M., serves as Independent Director at Ipsen S.A. since October 4, 2023. He has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 201...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pascal Touchon	President	5.3yrs	US$4.38m	0.58% € 248.7k
Anhco Nguyen	Executive VP and Chief Scientific & Technical Officer	3.3yrs	US$2.28m	0.25% € 108.8k
K. Murugan	Executive VP & Chief Legal Officer	4.4yrs	US$2.31m	0.22% € 95.3k
Eric Hyllengren	Executive VP & Chief Financial Officer	1.4yrs	geen gegevens	0.18% € 79.2k
Alex Chapman	Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Jill Henrich	Executive VP and Global Head of Regulatory Affairs & Quality	4yrs	geen gegevens	0.16% € 67.3k
Dan Maziasz	Executive VP & Chief Business Officer	3.7yrs	geen gegevens	geen gegevens
Rajani Dinavahi	Senior VP & Chief Medical Officer	less than a year	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AT20 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Pascal Touchon	President	5.3yrs	US$4.38m	0.58% € 248.7k
William Heiden	Independent Director	8.8yrs	US$237.23k	0.12% € 53.3k
Matthew Fust	Independent Director	10.5yrs	US$239.73k	0.042% € 18.3k
Carol Gallagher	Lead Independent Director	11.7yrs	US$260.23k	0.34% € 148.3k
Gregory Ciongoli	Independent Director	no data	geen gegevens	geen gegevens
Ameet Mallik	Independent Director	3.1yrs	US$219.52k	0.017% € 7.2k
Maria Roncarolo	Independent Director	4.3yrs	US$229.73k	0.026% € 11.1k

5.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AT20 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Atara Biotherapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Independent Director recently bought €95k worth of stock

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Recent updates

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought €95k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Third quarter 2022 earnings released: US$0.82 loss per share (vs US$0.91 loss in 3Q 2021)

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought €413k worth of stock

Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from A Combined Analysis of Phase 2 Tab-Cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease At the Ebmt 2021 Annual Meeting

Atara Biotherapeutics, Inc. Reports Operational Progress

New 90-day low: €13.90

Atara Biotherapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.999792 million.

Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219 at the 62 American Society of Hematology Annual Meeting

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors